The possibilities of monitoring the effectiveness of anticoagulant therapy using a thrombodynamics test in patients with left atrial appendage thrombosis with non-valvular atrial fibrillation: clinical cases
https://doi.org/10.35336/VA-1434
Abstract
Clinical observations of the possibility of using the thrombodynamics test (TD) in comparison with standard hemostasis tests in patients with non-valvular atrial fibrillation (AF) and detected thrombosis of the left atrial appendage against the background constant oral anticoagulants are presented. It has been shown that the transfer from one direct oral anticoagulant (DOACs) to another (with a different mechanism of action), as well as from DOACs to warfarin, can change the state of the blood plasma coagulation system towards both hyper- and hypocoagulation. Unlike standard hemostasis tests, TD can be used to assess the prothrombotic status of a patient with AF and personalized selection of effective anticoagulant therapy.
About the Authors
N. Yu. Khorkova
Tyumen Cardiology Research Center, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Khorkova Natalya
Tomsk, Tyumen, 625026, Melnikaite 111
T. P. Gizatulina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Tomsk, Tyumen, 625026, Melnikaite 111
A. V. Belokurova
Tyumen Cardiology Research Center, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Tomsk, Tyumen, 625026, Melnikaite 111
A. V. Mamarina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Tomsk, Tyumen, 625026, Melnikaite 111
References
1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021;42(5): 373-498. https://doi.org/10.1093/eurheartj/ehaa612.
2. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7): 4594. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4594.
3. Zhan Y, Joza J, Rawahi M, et al. Assessment and management of the Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation. Canadian Journal of Cardiology. 2018;34(3): 252-261. https://doi.org/10.1016/j.cjca.2017.12.008.
4. Krivosheev YS, Bashta DI, Krasilnikova SY, et al. Left atrial appendage thrombosis in atrial fibrillation - current status of the problem. Journal of Arrhythmology. 2019;26(4): 13-20 (In Russ.). https://doi.org/10.35336/VA-2019-4-13-20.
5. Khorkova NYu, Gizatulina TP, Belokurova AV, et al. Additional factors of thrombosis of the left atrial appendage in nonvalvular atrial fibrillation. Journal of Arrhythmology. 2020;27(2): 26-32. (In Russ.). https://doi.org/10.35336/VA-2020-2-26-32.
6. Ten Cate H, Henskens YM, Lancé MD. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Management. 2017;13: 457-467. https://doi.org/ 10.2147/VHRM.S126265.
7. Steffel J, Collins R, Matthias Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23: 1612- 1676. https://https://doi.org/10.1093/eurheartj/ehy136.
8. Gebekova ZA, Ivanov II., Asambayeva A, et al. Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants. Rational Pharmacotherapy in Cardiology. 2022;18(5): 544-552 (In Russ.). https://https://doi.org/10.20996/1819-6446-2022-09-07.
9. Gebekova ZA, Ivanov II, Kudrjavtseva AA, et al. New prospects for assessing the hemostasis system in atrial fibrillation and left atrial appendage thrombosis. Atherothrombosis. 2022;12(2): 103- 112. (In Russ.). https://doi.org/10.21518/2307-1109- 2022-12-2-103-112.
10. Vuimo T, Belikov E, Litinskaya O, Davtyan K. Efficiency of Thrombodynamics for Analysis of Hemostasis in Case of Transitory Ischemic Attack after Radiofrequency Ablation in a Patient with Paroxysmal Atrial Fibrillation. Am J Med Case Reports. 2015;3: 333-337. https://https://doi.org/10.12691/ajmcr-3-10-8.
11. Balandina AN, Koltsova EM, Shibeko AM, et al. Thrombodynamics: a new method to the diagnosis of hemostasis system disorders. Pediatric hematology/oncology and immunopathology. 2018;17(4): 114‒126 (In Russ.). https://doi.org/10.24287/1726-1708-2018-17-4-114-126.
12. Titaeva EV, Dobrovolsky AB. Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban. Aterotromboz = Atherothrombosis. 2020;(2): 96-104. (In Russ.). https://doi.org/10.21518/2307-1109-2020-2-96-104.
13. Billoir P, Barbay V, Joly LM, et al. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency with LMWH Calibrator. Ann Pharmacother. 2019;53(4): 341-347. https://doi.org/10.1177/1060028018811657.
14. Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk. Lymphoma. 2015;56(12): 3418-25. https://doi.org/10.3109/10428194.2015.1041385.
15. Balandina AN, Serebriyskiy II, Poletaev AV, et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS One. 2018;13(6): е0199900. https://doi.org/10.1371/journal.pone.0199900.
Review
For citations:
Khorkova N.Yu., Gizatulina T.P., Belokurova A.V., Mamarina A.V. The possibilities of monitoring the effectiveness of anticoagulant therapy using a thrombodynamics test in patients with left atrial appendage thrombosis with non-valvular atrial fibrillation: clinical cases. Journal of Arrhythmology. 2025;32(2):e1-e7. https://doi.org/10.35336/VA-1434
Views:
562
Email this article 